Juvenescence AI to develop first compounds generated by Insilico's deep-learned drug discovery engines

Juvenescence AI to develop first compounds generated by Insilico's deep-learned drug discovery engines:

Dementia Big
Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited.

http://ift.tt/2haEw5v